Acoramidis significantly reduced all-cause mortality in both wild-type and variant amyloid cardiomyopathy through 42 months of the ATTRibute-CM study. The study demonstrated consistent efficacy in ...
Hundreds of thousands of people diagnosed with cancer are still alive today but were never genetically tested, either because testing was not available or was not routinely offered at the time of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results